Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Sara M. Tolaney
Advertisement
Dr. Sara M. Tolaney is a medical oncologist and a senior physician. She is chief of the Division of Breast Oncology and director of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, as well as anassociate professor of medicine at Harvard Medical School, located in Boston.
Articles by Dr. Sara M. Tolaney
Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer.
Advertisement
Latest Updated Articles
Understanding the Best Practices Associated With CDK4/6 Therapy in Breast CancerPublished: March 10th 2025 | Updated:
